These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16131312)

  • 21. Defective IL-2 production by HIV-1-specific CD4 and CD8 T cells in an adolescent/young adult cohort.
    Kapogiannis BG; Henderson SL; Nigam P; Sharma S; Chennareddi L; Herndon JG; Robinson HL; Amara RR
    AIDS Res Hum Retroviruses; 2006 Mar; 22(3):272-82. PubMed ID: 16545014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1.
    Deeks SG; Martin JN; Sinclair E; Harris J; Neilands TB; Maecker HT; Hagos E; Wrin T; Petropoulos CJ; Bredt B; McCune JM
    J Infect Dis; 2004 Jan; 189(2):312-21. PubMed ID: 14722897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An antigenic threshold for maintaining human immunodeficiency virus type 1-specific cytotoxic T lymphocytes.
    Jin X; Ogg G; Bonhoeffer S; Safrit J; Vesanen M; Bauer D; Chen D; Cao Y; Demoitie MA; Zhang L; Markowitz M; Nixon D; McMichael A; Ho DD
    Mol Med; 2000 Sep; 6(9):803-9. PubMed ID: 11071274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load.
    Harrer T; Harrer E; Kalams SA; Barbosa P; Trocha A; Johnson RP; Elbeik T; Feinberg MB; Buchbinder SP; Walker BD
    J Immunol; 1996 Apr; 156(7):2616-23. PubMed ID: 8786327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlates of antiviral immune restoration in acute and chronic HIV type 1 infection: sustained viral suppression and normalization of T cell subsets.
    Dyer WB; Kuipers H; Coolen MW; Geczy AF; Forrester J; Workman C; Sullivan JS
    AIDS Res Hum Retroviruses; 2002 Sep; 18(14):999-1010. PubMed ID: 12396452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-1 low-level viremia affects T cell activation rather than T cell development in school-age children, adolescents, and young adults during antiretroviral therapy.
    Han J; Mu W; Zhao H; Hao Y; Song C; Zhou H; Sun X; Li G; Dai G; Zhang Y; Zhang F; Zeng H
    Int J Infect Dis; 2020 Feb; 91():210-217. PubMed ID: 31821891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Normalization of CD4+ cell numbers and reduced levels of memory CD8+ cells in blood and tonsillar tissue after highly active antiretroviral therapy in early HIV type-1 infection.
    Dyrhol-Riise AM; Voltersvik P; Røsok BI; Olofsson J; Asjö B
    AIDS Res Hum Retroviruses; 2000 Feb; 16(3):191-201. PubMed ID: 10710207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recognition patterns of HLA-A2-restricted human immunodeficiency virus-1-specific cytotoxic T-lymphocytes in a cohort of HIV-1-infected individuals.
    Schmitt-Haendle M; Bachmann O; Harrer E; Schmidt B; Bäuerle M; Harrer T
    Viral Immunol; 2005; 18(4):627-36. PubMed ID: 16359229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy.
    Wu H; Connick E; Kuritzkes DR; Landay A; Spritzler J; Zhang B; Spear GT; Kessler H; Lederman MM;
    AIDS Res Hum Retroviruses; 2001 Sep; 17(13):1231-40. PubMed ID: 11559422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
    Oxenius A; Price DA; Günthard HF; Dawson SJ; Fagard C; Perrin L; Fischer M; Weber R; Plana M; García F; Hirschel B; McLean A; Phillips RE
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13747-52. PubMed ID: 12370434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection.
    Montefiori DC; Hill TS; Vo HT; Walker BD; Rosenberg ES
    J Virol; 2001 Nov; 75(21):10200-7. PubMed ID: 11581388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between HIV-specific T helper responses and CTL activities in pediatric AIDS.
    Wasik TJ; Wierzbicki A; Whiteman VE; Trinchieri G; Lischner HW; Kozbor D
    Eur J Immunol; 2000 Jan; 30(1):117-27. PubMed ID: 10602033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of HIV-1-specific T-cells and increase of viral load during immunosuppressive treatment in an HIV-1 infected patient with Chlamydia trachomatis induced arthritis.
    Harrer T; Bäuerle M; Bergmann S; Eismann K; Harrer EG
    J Clin Virol; 2005 Nov; 34(3):224-30. PubMed ID: 16140574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection.
    Musey L; Hughes J; Schacker T; Shea T; Corey L; McElrath MJ
    N Engl J Med; 1997 Oct; 337(18):1267-74. PubMed ID: 9345075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perspectives on inducing efficient immune control of HIV-1 replication--a new goal for HIV therapeutics?
    Bucy RP; Kilby JM
    AIDS; 2001 Feb; 15 Suppl 2():S36-42. PubMed ID: 11424975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional patterns of HIV-1-specific CD4 T-cell responses in children are influenced by the extent of virus suppression and exposure.
    Correa R; Harari A; Vallelian F; Resino S; Munoz-Fernandez MA; Pantaleo G
    AIDS; 2007 Jan; 21(1):23-30. PubMed ID: 17148964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A long-term follow-up of an HIV type 1-infected patient reveals a coincidence of Nef-directed cytotoxic T lymphocyte effectors and high incidence of epitope-deleted variants.
    Singh MK; Janvier G; Calvez V; Coulaud P; Rivière Y
    AIDS Res Hum Retroviruses; 2001 Sep; 17(13):1265-71. PubMed ID: 11559426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.